Literature DB >> 17024438

Magnification-corrected photodynamic therapy.

Siamak Ansari-Shahrezaei1, Erdem Ergun, Robert Chong, Adnan Tufail, Andreas Wedrich, Michael Stur.   

Abstract

BACKGROUND: To present a method for performing photodynamic therapy (PDT) with a constant predictable light fluence based on actual laser spot magnification.
METHODS: A calibrated Gullstrand-type model eye with a scale of half circles in the centre of the artificial fundus was used for this study. The axial length of the model eye was set to different values ranging from 20 to 31 mm, and the actual laser spot magnification of four indirect condensing laser lenses were determined using a PDT laser unit.
RESULTS: Equations for determining the actual laser spot magnification were calculated for each laser lens. The total change in laser spot magnification from hyperopia (axial length 20 mm) to myopia (axial length 31 mm) was -20% to +24.8% for Mainster Standard lens (Ocular Instruments Inc, Bellevue, Washington, USA), -15.7% to +27.7% for Mainster Wide Field lens (Ocular Instruments Inc), -16.3% to +33.1% for Volk Transequator lens (Volk Optical Inc, Mentor, Ohio, USA), and -19.2% to +24.4% for Volk PDT Laser lens (Volk Optical Inc).
CONCLUSIONS: Axial length of the eye has a considerable effect on PDT laser spot magnification when an indirect laser lens is used. By calculating the actual laser spot magnification in conjunction with knowledge of the true greatest linear dimension of the neovascular lesion, the clinician may be able to deliver a constant predictable amount of light fluence to the fundus independent of the axial length of the PDT treating eye.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17024438     DOI: 10.1007/s00417-006-0419-y

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  23 in total

1.  Magnification characteristics of fundus imaging systems.

Authors:  A R Rudnicka; R O Burk; D F Edgar; F W Fitzke
Journal:  Ophthalmology       Date:  1998-12       Impact factor: 12.079

2.  [Determination of the real size of an object on the fundus of the living eye].

Authors:  H Littmann
Journal:  Klin Monbl Augenheilkd       Date:  1982-04       Impact factor: 0.700

3.  Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.

Authors:  U Schmidt-Erfurth; J W Miller; M Sickenberg; H Laqua; I Barbazetto; E S Gragoudas; L Zografos; B Piguet; C J Pournaras; G Donati; A M Lane; R Birngruber; H van den Berg; H A Strong; U Manjuris; T Gray; M Fsadni; N M Bressler
Journal:  Arch Ophthalmol       Date:  1999-09

4.  Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.

Authors:  J W Miller; U Schmidt-Erfurth; M Sickenberg; C J Pournaras; H Laqua; I Barbazetto; L Zografos; B Piguet; G Donati; A M Lane; R Birngruber; H van den Berg; A Strong; U Manjuris; T Gray; M Fsadni; N M Bressler; E S Gragoudas
Journal:  Arch Ophthalmol       Date:  1999-09

5.  Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.

Authors:  Mohammad Azab; David S Boyer; Neil M Bressler; Susan B Bressler; Ilona Cihelkova; Young Hao; Ilkka Immonen; Jennifer I Lim; Ugo Menchini; Joel Naor; Michael J Potter; Al Reaves; Philip J Rosenfeld; Jason S Slakter; Peter Soucek; H Andrew Strong; Andrea Wenkstern; Xiang Yao Su; Yit C Yang
Journal:  Arch Ophthalmol       Date:  2005-04

6.  Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment.

Authors:  D Husain; M Kramer; A G Kenny; N Michaud; T J Flotte; E S Gragoudas; J W Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-09       Impact factor: 4.799

7.  Influence of treatment parameters on selectivity of verteporfin therapy.

Authors:  Stephan Michels; Fabian Hansmann; Wolfgang Geitzenauer; Ursula Schmidt-Erfurth
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-01       Impact factor: 4.799

8.  Hyperopia and neovascularization in age-related macular degeneration.

Authors:  M A Sandberg; M J Tolentino; S Miller; E L Berson; A R Gaudio
Journal:  Ophthalmology       Date:  1993-07       Impact factor: 12.079

9.  Magnification-corrected indirect biomicroscopy of the optic nerve head.

Authors:  Siamak Ansari-Shahrezaei; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09-29       Impact factor: 3.117

10.  Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys.

Authors:  M Kramer; J W Miller; N Michaud; R S Moulton; T Hasan; T J Flotte; E S Gragoudas
Journal:  Ophthalmology       Date:  1996-03       Impact factor: 12.079

View more
  1 in total

1.  The effect of laser unit on photodynamic therapy spot size.

Authors:  Siamak Ansari-Shahrezaei; Susanne Binder; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-07-27       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.